Phase I trial of dose escalation for preoperative stereotactic radiosurgery for patients with large brain metastases
Neuro-Oncology · 05.09.2024 · 26 (9) · 1651-1659
DOI: 10.1093/neuonc/noae076 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, online erschienen am 24.04.2024. Verfasst von Erin S Murphy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Radiosurgery, Brain Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cleveland Clinic.
Abstract (Originalsprache)
Background
Single-session stereotactic radiosurgery (SRS) or surgical resection alone for brain metastases larger than 2 cm results in unsatisfactory local control. We conducted a phase I trial for brain metastases(>2 cm) to determine the safety of preoperative SRS at escalating doses.
Methods
Radiosurgery dose was escalated at 3 Gy increments for 3 cohorts based on maximum tumor dimension starting at: 18 Gy for >2–3 cm, 15 Gy for >3–4 cm, and 12 Gy for >4–6 cm. Dose-limiting toxicity was defined as grade III or greater acute toxicity.
Results
A total of 35 patients/36 lesions were enrolled. For tumor size >2–3 cm, patients were enrolled up to the second dose level (21 Gy); for >3–4 cm and >4–6 cm cohorts the third dose level (21 and 18 Gy, respectively) was reached. There were 2 DLTs in the >3–4 cm arm at 21 Gy. The maximum tolerated dose of SRS for >2–3 cm was not reached; and was 18 Gy for both >3–4 cm arm and >4–6 cm arm. With a median follow-up of 64.0 months, the 6- and 12-month local control rates were 85.9% and 76.6%, respectively. One patient developed grade 3 radiation necrosis at 5 months. The 2-year rate of leptomeningeal disease (LMD) was 0%.
Conclusions
Preoperative SRS with dose escalation followed by surgical resection for brain metastases greater than 2 cm in size demonstrates acceptable acute toxicity. The phase II portion of the trial will be conducted at the maximum tolerated SRS doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
- Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA.
ORCID-Profile: Erin S Murphy, Kailin Yang
Förderung
- NCI NIH HHS
- Cleveland Clinic
Zitieren
APA
Murphy, E. S., Yang, K., Suh, J. H., Yu, J. S., Stevens, G., Angelov, L., Vogelbaum, M. A., Barnett, G. H., Ahluwalia, M. S., Neyman, G., Mohammadi, A. M., & Chao, S. T. (2024). Phase I trial of dose escalation for preoperative stereotactic radiosurgery for patients with large brain metastases. Neuro-Oncology, 26(9), 1651-1659. https://doi.org/10.1093/neuonc/noae076
Vancouver
Murphy ES, Yang K, Suh JH, Yu JS, Stevens G, Angelov L, et al. Phase I trial of dose escalation for preoperative stereotactic radiosurgery for patients with large brain metastases. Neuro-Oncology. 2024;26(9):1651-1659. doi:10.1093/neuonc/noae076
BibTeX
@article{Murphy2024,
author = {Murphy, Erin S and Yang, Kailin and Suh, John H and Yu, Jennifer S and Stevens, Glen and Angelov, Lilyana and Vogelbaum, Michael A and Barnett, Gene H and Ahluwalia, Manmeet S and Neyman, Gennady and Mohammadi, Alireza M and Chao, Samuel T},
title = {Phase I trial of dose escalation for preoperative stereotactic radiosurgery for patients with large brain metastases},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {9},
pages = {1651--1659},
doi = {10.1093/neuonc/noae076}
}
EUVIMED